相关实验视频
Updated: Jul 25, 2025
10:36
Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
19.6K
新益生菌在神经退行性疾病中的治疗前景
Mingxia Bi1, Chang Liu1,2, Yulin Wang1
1State Key Laboratory of Microbial Biotechnology, Shandong University, Qingdao 266237, China.
Microorganisms
|June 28, 2023
概括
肠道微生物组失调与神经退行性疾病,如阿尔茨海默氏症和帕金森症有关. 新型益生菌有望通过调节肠-大脑轴来治疗这些疾病.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 越来越多的证据将肠道微生物组失调与神经退行性疾病,如阿尔茨海默病 (AD) 和帕金森病 (PD) 联系起来.
- 人们越来越认识到肠-大脑轴在调节中枢神经系统功能的作用.
- 这种观点改变了对神经退行症的理解,不仅仅是以大脑为中心的缺陷.
研究的目的:
- 审查当前对神经退行性疾病中肠道微生物组合的理解.
- 要总结由肠道微生物组产生的关键分子,这些分子影响神经退行.
- 讨论特定益生菌在治疗神经退行性疾病方面的治疗潜力.
主要方法:
- 关于肠道微生物组和神经退行症的临床和临床前研究的文献综述.
- 分析研究表明肠道微生物分子对神经退行过程的影响.
- 对调查神经退行性疾病益生菌干预的研究进行审查.
主要成果:
- 肠道微生物组失调是AD和PD的重要危险因素.
- 特定的肠道微生物代谢物和分子在神经炎症和神经退行症中起作用.
- 一些益生菌,包括*Clostridium butyricum*,*Akkermansia muciniphila*,*Faecalibacterium prausnitzii*和*Bacteroides fragilis*,具有神经保护性.
结论:
- 肠道微生物组是神经退行性疾病的发病的一个关键因素.
- 用益生菌准肠道微生物组为AD,PD和其他神经退行性疾病提供了一个有希望的治疗策略.
- 对特定益生菌菌株及其作用机制的进一步研究是必要的,以获得临床应用.
相关概念视频
01:29Microorganisms in Medicine and Therapeutics
68
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
68
01:22Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
01:15Parkinson's Disease: Overview
607
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
607
01:26Alzheimer's Disease: Overview
530
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
530
01:15Neurogenesis and Regeneration of Nervous Tissue
878
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
878
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K